Table 1.
Baseline characteristics between survival group and death group.
| Characteristic | Totals (n=322) | Survivals (n=242) | Deaths (n=80) | P |
|---|---|---|---|---|
| Age (year-old) | 60.51 ± 16.24 | 59.62 ± 16.41 | 63.21 ± 15.50 | 0.086a |
| Sex (F/M) | 110/212 | 76/166 | 34/46 | 0.078b |
| BMI (Kg/m2) | 24.27 ± 4.53 | 24.27 ± 4.50 | 24.26 ± 4.65 | 0.982a |
| HR (bpm) | 86 ± 22 | 87 ± 22 | 85 ± 22 | 0.411a |
| SBP (mmHg) | 125 ± 22 | 128 ± 23 | 118 ± 17 | 0.000a |
| DBP (mmHg) | 78 ± 15 | 80 ± 16 | 74 ± 12 | 0.000a |
| ALT (U/L) | 26.70 (17.73, 46.68) | 31.30 (21.80, 49.70) | 24.25 (15.83, 58.13) | 0.165c |
| AST (U/L) | 29.30 (22.90, 44.18) | 30.70 (24.00, 43.90) | 27.40 (21.70, 46.35) | 0.034c |
| ALB (g/L) | 37.36 ± 4.67 | 37.71 ± 4.67 | 36.27 ± 4.52 | 0.020a |
| Scr (umol/L) | 87.10 (72.05, 109.95) | 89.60 (76.00, 110.70) | 96.95 (78.63, 137.88) | 0.004c |
| BUN (mmol/L) | 7.19 (5.82, 9.54) | 7.28 (6.17, 8.71) | 8.49 (6.14, 10.90) | 0.000c |
| UA (mmol/L) | 473.0 (382.0, 582.0) | 479.0 (388.0, 576.0) | 526.5 (446.0, 748.0) | 0.029c |
| CysC (mg/L) | 1.31 (1.12, 1.63) | 1.31 (1.10, 1.57) | 1.52 (1.23, 1.77) | 0.001c |
| K (mmol/L) | 3.99 ± 0.51 | 3.96 ± 0.48 | 4.09 ± 0.56 | 0.042a |
| Na (mmol/L) | 139.76 ± 4.09 | 140.19 ± 3.81 | 138.49 ± 4.62 | 0.004a |
| Ca (mmol/L) | 2.25 ± 0.14 | 2.25 ± 0.14 | 2.25 ± 0.14 | 0.993a |
| HB (g/L) | 133.08 ± 20.81 | 135.24 ± 20.08 | 126.55 ± 21.70 | 0.001a |
| RDW (%) | 14.95 ± 4.78 | 14.75 ± 5.35 | 15.54 ± 2.29 | 0.205a |
| D-dimer (mg/L) | 0.75 (0.30, 1.72) | 0.59 (0.29, 1.58) | 0.94 (0.31, 2.84) | 0.001c |
| NT-proBNP (ng/L) | 1979 (1176, 4315) | 1775 (1205, 2933) | 2626 (1688, 6615) | 0.000c |
| cTnT (ng/L) | 61.80 ± 387.34 | 45.82 ± 295.11 | 101.74 ± 556.69 | 0.380a |
| CK-MB (U/L) | 35.34 ± 122.90 | 36.27 ± 139.96 | 32.98 ± 61.23 | 0.869a |
| TTE | ||||
| LVDd (mm) | 61.53 ± 12.51 | 61.35 ± 11.96 | 62.08 ± 14.12 | 0.661a |
| LVDs (mm) | 48.85 ± 14.01 | 48.67 ± 13.52 | 49.39 ± 15.53 | 0.697a |
| PASP (mmHg) | 42.0 (31.5, 53.0) | 40.0 (31.0, 48.0) | 48.0 (30.5, 60.5) | 0.005c |
| LVEF% | 42.50 ± 14.81 | 42.43 ± 14.57 | 42.71 ± 15.62 | 0.885a |
| NYHA | 0.228b | |||
| II (n%) | 48 (14.9) | 40 (16.5) | 8 (10.0) | |
| III (n%) | 181 (56.2) | 137 (56.6) | 44 (55.0) | |
| IV (n%) | 93 (28.9) | 65 (26.9) | 28 (35.0) | |
| Comorbidities | ||||
| IHD (n%) | 76 (23.6) | 55 (22.7) | 21 (26.3) | 0.545b |
| Cardiomyopathy (n%) | 130 (40.4) | 101 (41.7) | 29 (36.3) | 0.431b |
| VHD (n%) | 86 (26.7) | 63 (26.0) | 23 (28.8) | 0.663b |
| PHD (n%) | 23 (7.1) | 17 (7.0) | 6 (7.5) | 1.000b |
| Atrial fibrillation (n%) | 122 (37.9) | 94 (38.8) | 28 (35.0) | 0.596b |
| CHD (n%) | 10 (3.1) | 6 (2.5) | 4 (5.0) | 0.273b |
| HTN (n%) | 162 (50.3) | 125 (51.7) | 37 (46.3) | 0.440b |
| DM (n%) | 77 (23.9) | 55 (22.7) | 22 (27.5) | 0.450b |
| Pulmonary Infection (n%) | 66 (20.5) | 48 (19.8) | 18 (22.5) | 0.633b |
| Renal dysfunction (n%) | 20 (6.2) | 10 (4.1) | 10 (12.5) | 0.013b |
| Thyroid Dysfunction | 0.763b | |||
| Hyperthyroidism(n%) | 7 (2.2) | 6 (2.5) | 1 (1.3) | |
| Hypothyroidism(n%) | 1 (0.3) | 1 (0.4) | 0 (0) | |
| Smoking (n%) | 121 (37.6) | 98 (40.5) | 23 (28.8) | 0.064b |
F, Female; M, Male; BMI, Body Mass Index; HR, Heart Rate; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; ALT, Alanine Aminotransferase; AST, Aspartate Aminotransferase; ALB, Albumin; Scr, Serum Creatinine; BUN, Blood Urea Nitrogen; UA, Uric Acid; CysC, CystatinC; HB, Hemoglobin; RDW, Red blood cell Distribution Width; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; cTnT, cardiac troponin T; CK-MB, Creatine kinase-MB; LVDd, Left Ventricular Diastolic Dimension; LVDs, Left Ventricular Systolic Dimension; PASP, Pulmonary Artery Systolic Pressure; LVEF, Left Ventricular Ejection Fraction; IHD, Ischemic Heart Disease; VHD, Valvular Heart Disease; PHD, Pulmonary Heart Disease; CHD; Congenital Heart Disease; HTN, Hypertension; DM, Diabetes Mellitus.
aCalculated by unpaired t-test; bcalculated by Chi-square test; ccalculated by rank sum test.